Showing 1301-1310 of 3103 results for "".
- Five-Year Data from ALITHIOS Study on MS Disability Presented at AAN 2023https://practicalneurology.com/news/five-year-data-from-alithios-study-on-ms-disability-presented-at-aan-2023/2470163/According to long-term results of a study presented at the Americ
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- FDA Removes Category C Warning of Possible Risk in Pregnancy and Breast Feeding for MS Treatment Interferon Beta-1ahttps://practicalneurology.com/news/fda-removes-category-c-warning-of-possible-risk-in-pregnancy-and-breast-feeding-for-ms-treatment-interferon-beta-1a/2469280/The Food and Drug Administration (FDA) has removed the category C warning from the package insert for interferon beta-1a (Rebif; EMD Serono, Rockland, MA). The change is based on the revised Pregnancy and Lactation Labeling Rule (PLLR) and new safety data that the FDA also approved for inclu
- High-Dose Biotin Did Not Improve Disability for Individuals With Active Secondary Progressive MS in Phase 3 Trialhttps://practicalneurology.com/news/high-dose-biotin-did-not-improve-disability-for-individuals-with-active-secondary-progressive-ms-in-phase-3-trial/2469189/The second pivotal phase 3 trial (SPI2) (NCT02936037) of investigational high-dose biotin (MD1003, MedDay Pharmaceuticals, Boston, MA) did not improve disability for individuals with active secondary p
- FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MShttps://practicalneurology.com/news/fda-approves-cladribine-tabletsfirst-and-only-short-course-treatment-for-relapsing-remitting-ms/2468787/The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Cladribine has a dosing schedule tha
- Women with Multiple Sclerosis May Be Missing Breast Cancer Screeningshttps://practicalneurology.com/news/women-with-multiple-sclerosis-may-be-missing-breast-cancer-screenings/2469895/In a study published in Neurology, women with multiple sclerosis (MS) were less likely to have breast cancer detected through screenings than women without MS. Women with MS were also more likely to have colorectal cancers detected early with screenings compared with women without MS. Th
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an
- Short-Term Stress Management Protocol Improves Objective and Self-Reported Measures of Stress and Mood in Patients with MS According to New Researchhttps://practicalneurology.com/news/short-term-stress-management-protocol-improves-objective-and-self-reported-measures-of-stress-and-mood-in-patients-with-ms-according-to-new-research/2470202/Research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) suggests that participating in a program providing short-term psychotherapy in stress management techniques improves mood
- T-Cell Therapy Targeting Epstein-Barr Virus Provided Sustained Disability Improvement for Progressive MS in Phase 1a Clinical Trialhttps://practicalneurology.com/news/t-cell-therapy-targeting-epstein-barr-virus-provided-sustained-disability-improvement-for-progressive-ms-in-phase-1a-clinical-trial/2469377/An Epstein-Barr virus (EBV)-targeting, off-the-shelf allogeneic T-Cell therapy (ATA188; Atara, South San Francisco, CA) was well tolerated and showed signs of efficacy measured as sustained disability improvement (SDI) in participants with progressive multiple sclerosis (PMS). In this Phase 1a 12
- FDA Approves Diroximel Fumarate—A Second Generation Fumarate With Fewer Side Effects—for Treatment of Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-diroximel-fumaratea-second-generation-fumarte-with-fewer-side-effectsfor-treatment-of-multiple-sclerosis/2469063/The Food and Drug Administration has approved diroximel fumarate (Vumerity; Biogen, Cambridge, MA and Alkermes, Dublin, Ireland) for the treatment of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing remitting MS (RRMS), and active secondary progressive MS (SPMS). &n